Out-of-Specification (OOS) Investigations: Laboratory Phase I Guidelines and FDA Compliance
Handling Out-of-Specification (OOS) laboratory data is one of the most critical aspects of FDA audit integrity. An OOS result occurs when an analytical test result falls outside the defined limits established in monographs, drug master files, or batch records. In this article, we detail the step-by-step regulatory expectations for Phase I laboratory investigations.
The Immediate Phase I Lab Investigation
When an analyst obtains a result that is out of specification, they must not delete it or re-run the sample hoping for a passing result. The raw data must be preserved, and the analyst must immediately notify their QC supervisor. The laboratory must then initiate a Phase I investigation to check if the OOS is due to an obvious laboratory error. Obvious errors include:
- Calculation errors or incorrect data entry.
- Instrument malfunction (such as detector noise, bubble in HPLC line, or power failure).
- Analyst pipetting error or incorrect preparation of reagents.
Requirements for Re-testing
If the Phase I investigation confirms a clear laboratory error, the original result is invalidated. The analyst can prepare new samples and re-run the assay. However, if no clear laboratory error is identified, the result cannot be ignored. The investigation proceeds to Phase II, which involves a full-scale manufacturing process review and potential re-testing of the sample.
For re-testing, the sample must be analyzed following a pre-approved protocol detailing the number of replicates to be run (typically 5 to 7) and who will perform the test. If all re-test results pass, and the manufacturing review is clean, the batch can be released, but the original OOS and all investigation steps must remain fully documented in the batch folder to defend the QA decision during audits.
Subscribe to our monthly GMP newsletter
Receive Hyderabad pharmaceutical regulatory updates directly to your inbox.
Join Newsletter List